Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Rayner

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Diabetes, Obesity & Metabolism|February 15, 2019
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
Journal of Nephrology|August 4, 2024
Consistency of alerts generated by, and implementation of, the NHS England acute kidney injury detection algorithm in English laboratoriesRyan Aylward, Anna Casula, Nicki Tiffin, et al.
Journal of Personalized Medicine|July 27, 2024
Genetic Variation in <i>ABCB1</i>, <i>ADRB1</i>, <i>CYP3A4</i>, <i>CYP3A5</i>, <i>NEDD4L</i> and <i>NR3C2</i> Confers Differential Susceptibility to Resistant Hypertension among South AfricansJonathan N Katsukunya, Erika Jones, Nyarai D Soko, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2010
Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy databaseIkechi Okpechi, Charles Swanepoel, Maureen Duffield, et al.
Clinical Nephrology|April 22, 2017
Mortality risk factors in intensive care unit patients with acute kidney injury requiring renal replacement therapy: a retrospective cohort study
Michael Schmitz, Frank P Tillmann, Ausra Paluckaite, et al.
Kidney360|April 4, 2022
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory AnalysisKatherine R Tuttle, Brian Rayner, Mark C Lakshmanan, et al.
The Lancet. Diabetes & Endocrinology|June 19, 2018
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trialKatherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
BMC Public Health|January 14, 2014
Efficacy of a text messaging (SMS) based intervention for adults with hypertension: protocol for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trialKirsty Bobrow, Thomas Brennan, David Springer, et al.
The Lancet. Diabetes & Endocrinology|September 30, 2018
GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' replyKatherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
Frontiers in Genetics|June 19, 2025
<i>NOS3</i> rs3918188C>A is associated with susceptibility to resistant hypertension while <i>CES1</i> genetic variation was not associated with resistant hypertension among South AfricansJonathan N Katsukunya, Revina Naicker, Nyarai D Soko, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Diabetes, Obesity & Metabolism|February 15, 2019
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
Journal of Nephrology|August 4, 2024
Consistency of alerts generated by, and implementation of, the NHS England acute kidney injury detection algorithm in English laboratoriesRyan Aylward, Anna Casula, Nicki Tiffin, et al.
Journal of Personalized Medicine|July 27, 2024
Genetic Variation in <i>ABCB1</i>, <i>ADRB1</i>, <i>CYP3A4</i>, <i>CYP3A5</i>, <i>NEDD4L</i> and <i>NR3C2</i> Confers Differential Susceptibility to Resistant Hypertension among South AfricansJonathan N Katsukunya, Erika Jones, Nyarai D Soko, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2010
Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy databaseIkechi Okpechi, Charles Swanepoel, Maureen Duffield, et al.
Clinical Nephrology|April 22, 2017
Mortality risk factors in intensive care unit patients with acute kidney injury requiring renal replacement therapy: a retrospective cohort study
Michael Schmitz, Frank P Tillmann, Ausra Paluckaite, et al.
Kidney360|April 4, 2022
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory AnalysisKatherine R Tuttle, Brian Rayner, Mark C Lakshmanan, et al.
The Lancet. Diabetes & Endocrinology|June 19, 2018
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trialKatherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
BMC Public Health|January 14, 2014
Efficacy of a text messaging (SMS) based intervention for adults with hypertension: protocol for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trialKirsty Bobrow, Thomas Brennan, David Springer, et al.
The Lancet. Diabetes & Endocrinology|September 30, 2018
GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' replyKatherine R Tuttle, Mark C Lakshmanan, Brian Rayner, et al.
Frontiers in Genetics|June 19, 2025
<i>NOS3</i> rs3918188C>A is associated with susceptibility to resistant hypertension while <i>CES1</i> genetic variation was not associated with resistant hypertension among South AfricansJonathan N Katsukunya, Revina Naicker, Nyarai D Soko, et al.
Pageof 8